Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TransMedics Group, Inc. reported full year 2023 results: revenue $180 million to $190 million. Guidance raised.
- Period
- full year 2023
- Revenue
- $180 million to $190 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
TransMedics is updating its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s prior year revenue. TransMedics’ prior 2023 revenue guidance was $160 million to $170 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..
- Period
- quarter ended June 30, 2023
- Net income
- Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
- Result
- reported results
Exact text from the filing
Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022 .
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.98
TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..
- Period
- quarter ended June 30, 2023
- Net income
- Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
- Result
- reported results
Exact text from the filing
Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.
View on SEC.gov